Quarterly ResultMay 6, 2026, 04:32 PM
Alvotech Q1 Revenue $105.9M; Strategic Manufacturing Deal
AI Summary
Alvotech reported Q1 2026 total revenues of $105.9 million and adjusted EBITDA of $24.4 million, which were impacted by production slowdowns for facility improvements. The company announced a strategic manufacturing agreement with FUJIFILM Biotechnologies to establish a U.S.-based second source of commercial supply. Key pipeline advancements include an EMA submission for AVT16 and AVT80 (Entyvio biosimilars) and the commencement of a pivotal study for AVT29 (Eylea HD biosimilar). Alvotech projects 2026 total revenues of $650-$700 million and adjusted EBITDA of $180-$220 million.
Key Highlights
- Q1 2026 total revenues were $105.9M, compared to $132.8M in the same period last year.
- Q1 2026 adjusted EBITDA was $24.4M with a Gross Margin of 57%.
- Submitted Marketing Authorization Application to EMA for AVT16 and AVT80 (Entyvio biosimilars).
- Commenced pivotal efficacy and safety study for AVT29 for Eylea HD biosimilar.
- Entered strategic manufacturing agreement with FUJIFILM Biotechnologies for U.S.-based commercial supply.
- Anticipates 2026 total revenues in the range of $650-$700M.
- Anticipates 2026 adjusted EBITDA in the range of $180-$220M.